|
|
Drugging the unfolded protein response in acute leukemias
Behzad Kharabi Masouleh
,
Eric Chevet
,
Jens Panse
,
Edgar Jost
,
Michael O'Dwyer
et al.
Journal articles
hal-01187303v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
Bijal D Shah
,
Armin Ghobadi
,
Olalekan O Oluwole
,
Aaron C Logan
,
Nicolas Boissel
et al.
Journal articles
hal-03260932v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
Bijal Shah
,
Armin Ghobadi
,
Olalekan Oluwole
,
Aaron Logan
,
Nicolas Boissel
et al.
Conference papers
hal-04069384v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Deregulated expression of the HSP40 family members Auxilin-1 and -2 is indicative of proteostasis imbalance and predicts patient outcome in Ph+ leukemia
Margherita Vieri
,
Huimin Geng
,
John B. Patterson
,
Jens Panse
,
Stefan Wilop
et al.
Journal articles
hal-01274235v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
Bijal Shah
,
Armin Ghobadi
,
Olalekan Oluwole
,
Aaron Logan
,
Nicolas Boissel
et al.
Journal articles
hal-04069449v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|